Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.
Nature
; 482(7383): 89-93, 2012 Jan 04.
Article
em En
| MEDLINE
| ID: mdl-22217938
ABSTRACT
Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have typically shown post-infection virological control, but protection against acquisition of infection has previously only been reported against neutralization-sensitive virus challenges. Here we demonstrate vaccine protection against acquisition of fully heterologous, neutralization-resistant simian immunodeficiency virus (SIV) challenges in rhesus monkeys. Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines expressing SIV(SME543) Gag, Pol and Env antigens resulted in an 80% or greater reduction in the per-exposure probability of infection against repetitive, intrarectal SIV(MAC251) challenges in rhesus monkeys. Protection against acquisition of infection showed distinct immunological correlates compared with post-infection virological control and required the inclusion of Env in the vaccine regimen. These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vírus da Imunodeficiência Símia
/
Vacinas contra a SAIDS
/
Anticorpos Neutralizantes
/
Macaca mulatta
Limite:
Animals
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article